Spots Global Cancer Trial Database for premenopausal breast cancer
Every month we try and update this database with for premenopausal breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients | NCT06225284 | Triple Negative... Premenopausal B... | Goserelin Aceta... | 18 Years - 50 Years | National Taiwan University Hospital | |
| Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer | NCT02990845 | Premenopausal B... | Pembrolizumab/ ... | 20 Years - | National Taiwan University Hospital | |
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | NCT05801705 | Hormone-recepto... Premenopausal B... Breast Cancer P... Ovarian Functio... | Aromatase inhib... ovarian functio... Tamoxifen toremifene | 18 Years - 60 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer | NCT02483767 | Breast Cancer | goserelin standard chemot... | 18 Years - 45 Years | Peking Union Medical College Hospital | |
| A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer | NCT01546649 | Premenopausal B... | TAP-144-SR(6M) TAP-144-SR(3M) | 20 Years - | Takeda | |
| A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer | NCT01546649 | Premenopausal B... | TAP-144-SR(6M) TAP-144-SR(3M) | 20 Years - | Takeda | |
| Ovarian Reserve in Premenopausal Breast Cancer | NCT01726322 | Premenopausal B... Breast Cancer | 18 Years - 50 Years | Cancer Trials Ireland | ||
| Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study | NCT05801705 | Hormone-recepto... Premenopausal B... Breast Cancer P... Ovarian Functio... | Aromatase inhib... ovarian functio... Tamoxifen toremifene | 18 Years - 60 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer | NCT02483767 | Breast Cancer | goserelin standard chemot... | 18 Years - 45 Years | Peking Union Medical College Hospital | |
| OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk | NCT05333328 | Breast Cancer Estrogen Recept... HER2-negative B... Premenopausal B... Node-positive B... | Ovarian functio... | 20 Years - 50 Years | Gangnam Severance Hospital | |
| Ovarian Reserve in Premenopausal Breast Cancer | NCT01726322 | Premenopausal B... Breast Cancer | 18 Years - 50 Years | Cancer Trials Ireland | ||
| The Immune System's Response to Young Women's Breast Cancer | NCT01503190 | Breast Cancer Breast Cancer a... | 18 Years - | University of Colorado, Denver | ||
| Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | NCT05720260 | Premenopausal B... Metastatic Brea... ER Positive Bre... | Goserelin Fulvestrant Capivasertib Durvalumab | 20 Years - | National Taiwan University Hospital | |
| The Immune System's Response to Young Women's Breast Cancer | NCT01503190 | Breast Cancer Breast Cancer a... | 18 Years - | University of Colorado, Denver | ||
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | NCT05982093 | Breast Cancer HER2-negative B... Hormone Recepto... Premenopausal B... | Elacestrant Triptorelin | 35 Years - | SOLTI Breast Cancer Research Group | |
| Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients | NCT04997941 | Premenopausal B... Hormone Recepto... | Tamoxifen Oral ... Assessment of K... Surgery | 20 Years - 48 Years | Seoul National University Hospital | |
| Ovarian Reserve in Premenopausal Breast Cancer | NCT01726322 | Premenopausal B... Breast Cancer | 18 Years - 50 Years | Cancer Trials Ireland | ||
| Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer | NCT02483767 | Breast Cancer | goserelin standard chemot... | 18 Years - 45 Years | Peking Union Medical College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
